Man who let snakes bite him 200 times spurs new antivenom hope
PARIS - Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.
Four days later, he woke up from a coma.
"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.
This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.
From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.
Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.
After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.
But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.
The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.
AFP/File | Tony KARUMBA
This would fill a major need, because currently, most antivenoms only cover one or a few of the world's 600 venomous snakes.
Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.
These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.
- 'Pain every time' -
Friede's first bite was from a harmless garter snake when he was five years old.
"I was afraid, I cried, I ran away," said Friede, now 57.
Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.
Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.
How antivenom is made has changed little over the last 125 years.
Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.
However, this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from a horse that can cause serious side-effects, including anaphylactic shock.
"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.
He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.
"There is pain every time," he said.
- 'Proud' -
For years, the scientists he contacted to take advantage of his immunity refused to bite.
Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.
Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.
When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."
AFP/File | Tony KARUMBA
"I've been waiting for this call for a long time," came the response, Glanville said.
The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.
It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.
The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.
Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.
Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.
Friede said he was "proud" to have made a "small difference" in medical history.
Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.
But he hopes to get bitten by snakes again in the future.
"I do miss it," he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TimesLIVE
6 hours ago
- TimesLIVE
Red tape stops SA kids from getting ADHD meds
Attention deficit and hyperactivity disorder (ADHD) affects between 5% and 7% of schoolgoing children, but because doctors can only prescribe treatment for a month at a time, many kids in South Africa, especially those who can't afford monthly doctor's visits, don't access medication regularly. Methylphenidate, a central nervous system stimulant that can significantly reduce symptoms in about 70% of users with the condition and that the World Health Organization (WHO) recommends for the treatment of ADHD, helps people with ADHD to concentrate better, and to be less impulsive and overactive. Studies have shown that when the methylphenidate — the gold standard for ADHD treatment — is used correctly, children's school marks improve and they become better equipped to develop social skills. In other words, effective ADHD treatment doesn't just help schoolgoers with ADHD to sit still and focus in class, but it also supports them to learn and socialise — outcomes that form the foundation of a healthy and productive adulthood. Methylphenidate is, however, classified as a schedule six drug in South Africa, placing it in the same regulatory category as medicines with a high potential for abuse. Pharmacies are therefore only allowed to dispense the medicine to people with doctors' prescriptions, and by law, physicians can only prescribe 30 days' worth of methylphenidate treatment at a time. This means patients need to visit their doctor each month for a new prescription, so in the private sector they'd need to pay for a doctor's visit each month, on top of paying for the medication, and in the public sector patients would need to take a day each month to queue up at their local clinic — and they'd have to make sure it's a day on which a doctor, as opposed to only nurses, are available at their health facility. The current scheduling, as a result, creates huge administrative and financial difficulties for patients and caregivers when they try to get treated, especially for those navigating ADHD's very symptoms: executive dysfunction, forgetfulness and inattention. As a psychiatrist, working in both the public and private healthcare sector, I've seen first hand the toll that untreated ADHD takes on children, adults and families — from fractured educational journeys to unemployment, depression, addiction and even suicide. These are not theoretical risks but daily realities for many South Africans. And yet one of the biggest obstacles that locks people out of treatment — our own healthcare policies — remains unchanged.
Eyewitness News
a day ago
- Eyewitness News
Gaza rescuers say Israeli fire kills 22 near aid site as truce talks falter
RAFAH - Gaza rescuers said Israeli gunfire killed at least 22 Palestinians near a US-backed aid distribution site on Sunday, shortly after Washington rejected Hamas's response to a ceasefire proposal as "totally unacceptable". International critics, including some allies, have condemned Israel over the humanitarian crisis in war-ravaged Gaza, where the United Nations has warned the entire population faces famine after a more than two-month blockade on aid. Israel recently introduced a revamped aid delivery mechanism in cooperation with a newly formed US-backed organisation, bypassing the longstanding UN-led system. The organisation, the Gaza Humanitarian Foundation, says it has distributed hundreds of thousands of meals since operations began last week, but the rollout has been marked by chaotic scenes at the limited number of distribution centres, as well as reports of casualties from Israeli fire nearby. Gaza civil defence spokesman Mahmud Bassal told AFP that Israeli fire near one of the centres in the southern city of Rafah on Sunday morning had killed "at least 22, with more than 120 wounded, including children". AFP images from the scene showed some civilians transporting bodies on donkey carts, as others carried away boxes and bags of aid under the low, early-morning sun. The casualties were taken to Nasser Hospital in Khan Yunis, Bassal said. 'CHAOS BROKE OUT' Displaced Beit Lahia resident Sameh Hamuda, 33, told AFP he had walked from Gaza City and spent the night with relatives in a tent near Rafah before heading to the aid centre around 5:00 am to wait among a crowd of people. "They began distributing aid, but suddenly, quadcopter drones opened fire on the people, and tanks started shooting heavily. Several people were killed right in front of me," he said. "I ran and survived. Death follows you as long as you're in Gaza." Abdullah Barbakh, 58, described "chaos, screaming, and overcrowding" at the scene. "The army opened fire from drones and tanks. Chaos broke out, and the area was filled with martyrs and wounded. I don't understand why they call people to the aid centres and then open fire on them," he said. "What are we supposed to do?" Asked for comment, the Israeli military said it was "unaware of injuries caused by IDF (army) fire within the Humanitarian Aid distribution site. The matter is still under review." Separately, Bassal said one person was killed and many others wounded by Israeli gunfire near another aid point in central Gaza. Only limited amounts of aid have entered Gaza since Israel recently eased a more than two-month total blockade, with a spokesman for the UN humanitarian agency recently calling the territory "the hungriest place on earth". The United Nations also reported looting of its trucks and warehouses last month. GHF, which employs contracted US security, said it had distributed 2.1 million meals as of Friday. The United Nations and other major aid groups have refused to cooperate with the organisation, saying it contravened basic humanitarian principles and appeared designed to cater to Israeli military objectives. GHF did not immediately respond to a request for comment on the reported deaths. TRUCE TALKS Nearly 20 months into the war, negotiations for a ceasefire and a deal to free the hostages held by militants have failed to produce a breakthrough since the last brief truce collapsed in March. Israel has since intensified its operations to destroy Hamas. The Palestinian militant group said Saturday that it had responded positively to a US-backed ceasefire proposal, but had emphasised the need for a permanent ceasefire -- long a sticking point for Israel. Washington's main negotiator on Gaza, envoy Steve Witkoff, immediately criticised Hamas's reply as "totally unacceptable", an assessment echoed by Israel, which on Friday had warned Hamas to either accept the deal "or be annihilated". Witkoff urged the group to "accept the framework proposal we put forward". "That is the only way we can close a 60-day ceasefire deal in the coming days in which half of the living hostages and half of those who are deceased will come home to their families and in which we can have... substantive negotiations in good-faith to try to reach a permanent ceasefire," he added in a post on X. Of the 251 hostages taken during Hamas's October 7, 2023 attack, 57 remain in Gaza, including 34 the Israeli military says are dead. The health ministry in Hamas-run Gaza said on Saturday that at least 4,117 people have been killed in the territory since Israel resumed its offensive on March 18, taking the war's overall toll to 54,381, mostly civilians. Hamas's attack on Israel resulted in the deaths of 1,218 people, mostly civilians, according to an AFP tally based on official figures.
eNCA
2 days ago
- eNCA
Man who let snakes bite him 200 times spurs new antivenom hope
PARIS - Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him. Four days later, he woke up from a coma. "I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin. This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time. From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times. Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home. After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists. But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom. The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom. AFP/File | Tony KARUMBA This would fill a major need, because currently, most antivenoms only cover one or a few of the world's 600 venomous snakes. Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization. These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas. - 'Pain every time' - Friede's first bite was from a harmless garter snake when he was five years old. "I was afraid, I cried, I ran away," said Friede, now 57. Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted. Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom. How antivenom is made has changed little over the last 125 years. Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom. However, this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from a horse that can cause serious side-effects, including anaphylactic shock. "I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said. He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes. "There is pain every time," he said. - 'Proud' - For years, the scientists he contacted to take advantage of his immunity refused to bite. Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom. Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites. When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood." AFP/File | Tony KARUMBA "I've been waiting for this call for a long time," came the response, Glanville said. The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib. It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six. The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia. Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies. Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down. Friede said he was "proud" to have made a "small difference" in medical history. Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues. But he hopes to get bitten by snakes again in the future. "I do miss it," he said.
